Renalytix Plc (LON:RENX) Insider James Renwick McCullough Purchases 25,000 Shares

Renalytix Plc (LON:RENX) insider James Renwick McCullough acquired 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average cost of GBX 9 ($0.11) per share, with a total value of £2,250 ($2,852.07).

James Renwick McCullough also recently made the following trade(s):

• On Thursday, December 5th, James Renwick McCullough acquired 53,300 shares of Renalytix stock. The shares were acquired at an average cost of GBX 8 ($0.10) per share, with a total value of £4,264 ($5,404.99).

Renalytix Stock Up 5.6 %

Shares of LON RENX opened at GBX 9.50 ($0.12) on Friday. Renalytix Plc has a 12-month low of GBX 6.50 ($0.08) and a 12-month high of GBX 74.90 ($0.95). The stock has a market cap of £15.76 million, a PE ratio of -39.58 and a beta of 2.10. The company has a current ratio of 0.53, a quick ratio of 2.42 and a debt-to-equity ratio of 173.95. The company has a 50-day moving average of GBX 7.76 and a 200 day moving average of GBX 11.23.

Renalytix Company Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.